yung-evidencebasedguidelines-2020.pdf (534.09 kB)
Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology
journal contribution
posted on 2020-01-01, 00:00 authored by T R E Barnes, R Drake, C Paton, S J Cooper, B Deakin, I N Ferrier, C J Gregory, P M Haddad, O D Howes, I Jones, E M Joyce, S Lewis, A Lingford-Hughes, J H MacCabe, D C Owens, M X Patel, J M A Sinclair, J M Stone, P S Talbot, R Upthegrove, A Wieck, Alison YungAlison YungThese updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement.
History
Journal
Journal of PsychopharmacologyVolume
34Issue
1Pagination
3 - 78Publisher
SageLocation
London, Eng.Publisher DOI
Link to full text
ISSN
0269-8811eISSN
1461-7285Language
EnglishPublication classification
C1 Refereed article in a scholarly journalUsage metrics
Categories
No categories selectedKeywords
1ST EPISODE PSYCHOSISACTING INJECTABLE ANTIPSYCHOTICSANTIPSYCHOTIC MEDICATION ADHERENCECLINICAL HIGH-RISKClinical NeurologyELECTRONIC MONITORING MEMS(R)GuidelineLife Sciences & BiomedicineNEUROLEPTIC MALIGNANT SYNDROMENeurosciencesNeurosciences & NeurologyPharmacology & PharmacyPsychiatrypsychopharmacologyQUALITY-OF-LIFERANDOMIZED CONTROLLED-TRIALschizophreniaScience & TechnologyTREATMENT-RESISTANT SCHIZOPHRENIAULTRA-HIGH RISK
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC